(1) Secondary pathophysiology in sphingolipidoses and overlap of a final common pathway of lipotoxicity between sphingolipidoses and "acquired metabolic diseases" such as obesity, type 2 diabetes, MASLD, aging, neurodegenerative diseases
(2) Patient preferences and risk tolerance regarding gene therapy in lysosomal storage diseases